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Previous reports have suggested that treatment with cytokine-induced killer (CIK) cells may beneﬁt patients with various types of
tumor.TheaimofthisstudywastoevaluatetheantitumoreﬀectsofCIKcellsagainstthecolorectalcancerlineSW1116invitroand
in vivo. CIK cells were generated routinely from peripheral blood mononuclear cells of healthy human donors, and the number of
CD3+CD56+ cells was expanded more than 1300-fold after 14-day culture. At an eﬀector:target cell ratio of 50:1, the percentage
lysis of SW1116 cells reached 68% in the presence of CIK cells, Experimental mice injected with SW1116 cells subcutaneously
were divided randomly into four groups: untreated, 5-ﬂuorouracil (5-FU)-treated, CIK-consecutive treated (injected once/day)
and CIK-interval treated (injected once every 5 days). CIK cells were injected abdominally ﬁve times in total. Compared with the
untreated group, xenograft growth was inhibited greatly by CIK treatment, to nearly the same extent as with 5-FU treatment. We
demonstratedthatthenecroticareainthetumorxenograftwasmarkedlylargerintheCIK-treatedgroupsthanintheothergroups.
These ﬁndings suggest that CIK-based immunotherapy may represent an eﬀective choice for patients with colorectal cancer.
1.Introduction
Colorectal cancer is the third most common cause of death
due to cancer in the Western world [1]. In 2009, it was esti-
mated that 75,590 men and 71,380 women were diagnosed
with colorectal cancer in the United States [2]. Despite major
advances in medical technology and therapy, colorectal
cancer still only has an overall 5-year survival rate of 20%–
50%. The disease is characterized by the development of
a tumor in the large bowel that then spreads throughout
the body. Although the primary tumor can be treated
b yo n l ys u r g e r y ,t r e a t m e n to fm e t a s t a s e sr e q u i r e ss o m e
form of adjuvant therapy, such as radioimmunotherapy
or chemotherapy. New therapeutic methods are needed to
prolong survival.
Adoptive cellular immunotherapy involves the transfer
of immune cells that have been expanded and activated ex
vivo into patients to eliminate cancer cells. This approach is
becoming an important eﬀective method for cancer therapy.
In recent years, the application of cytokine-induced killer
(CIK) cells has evolved from experimental observations
into early clinical studies. These cells have been shown to
have encouraging preliminary eﬃcacy towards susceptible
autologous and allogeneic tumor cells in both therapeutic
and adjuvant settings. CIK cells have a high rate of prolifer-
ation; they are derived from peripheral blood mononuclear
cells (PBMCs) and are cultured with interferon-γ (INF-γ),
anti-CD3 antibodies, and interleukin (IL)-2 [3, 4]. Among
CIK cells, CD3+CD56+ cells are the main eﬀector cells and
demonstrate the most potent cytolytic activity [3, 5]. They
have been described as highly eﬃcient cytotoxic eﬀector
cells that are capable of recognizing and lysing tumor cell
targets in a nonmajor histocompatibility complex-(MHC-)
restrictedfashion[6,7].CIKcellshavebeenshowntotargeta
variety of types of tumor and can exert their cytotoxic eﬀects
following systemic delivery [8].
CIK cells have been found to be highly eﬀective at
purging autologous bone marrow in patients with chronic
myelogenous leukemia [9]. The antitumor eﬀect of CIK
cells has also been observed on many solid tumors, such as2 Clinical and Developmental Immunology
hepatoma, lung, and gastric cancers [10–12]. Furthermore,
CIK cells can improve the immune function and clinical
symptoms of cancer patients. Importantly, the toxicity of
CIK cells is minimal, and there is no graft-versus-host reac-
tion associated with their use [5]. In spite of their beneﬁcial
features, the cytotoxic activity of CIK cells against human
colorectal cancer cells has not been clearly deﬁned. In the
study reported herein, we evaluated the antitumor activity
of CIK cells in vitro against the human colorectal cancer cell
line SW1116 and in vivo in a nude mouse xenograft model.
2.MaterialsandMethods
2.1. Cell Culture. Human colorectal cancer cells (SW1116)
and human glioblastoma cells (U251) were originally
obtained from the American Type Culture Collection
(ATCC, Rockvile, MD, USA) and cultured in high-glucose
Dulbecco’s modiﬁed Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum, 100U/ml penicillin
and 100mg/ml streptomycin in a humidiﬁed 5% CO2
incubator at 37◦C.
2.2. Generation of CIK Cells. After the healthy blood donor
had given informed consent, 10ml of blood was collected
fromeachinevacuatedtubesthatcontainedheparin.Human
PBMCs were isolated from fresh blood by Ficoll-Hypaque
density gradient centrifugation. The PBMCs were washed
three times, adjusted to a ﬁnal concentration of 2 ×
106 cells/mlwithCIKmedium(Takara,Japan)supplemented
with 0.6% autogeneic serum, and then cultured in 75cm2
culture ﬂasks that had been coated with 8ml of PBS that
contained 5μg/ml antihuman CD3 monoclonal antibody
(Takara, Japan) at 4◦C overnight. On day 0 of culture, we
added 1000U/ml recombinant human IFN-γ (PeproTech,
USA) and 1000U/ml recombinant human IL-2 (rhIL-2,
PeproTech, USA) to the culture medium. The cells were
cultured in a humidiﬁed 5% CO2 incubator at 37◦C. The
cells were transferred from the coated ﬂasks to fresh ﬂasks
after four days. Every three days, fresh CIK medium and
1000U/ml rhIL-2 were added. After culture for 14 days,
approximately 1 × 109 CIK cells were harvested per ﬂask,
with a survival rate of >95%.
2.3. Phenotypic Analysis of CIK Cells. At o t a lo f5× 105 CIK
cells were harvested and washed twice with PBS. The cells
were resuspended in 100μl of PBS, labeled with 15μlo f
antibodiesagainstCD4/8/3(FITC-conjugatedanti-CD4,PE-
conjugated anti-CD8, and PerCP-conjugated anti-CD3; BD,
USA)and 5μlof anti-CD56 antibody (APC-conjugatedanti-
CD56; BD, USA) in the dark for 30min at 4◦C, and then
washedtwice.Fluorescence-activatedcellsorting(FACS)was
then performed. The phenotype of PBMCs was analyzed as a
control.
2.4. MTT Cytotoxicity Test of CIK Cells In Vitro. SW1116
cells were plated in 96-well plates in triplicate at a density
of 4 × 104 cells/well. After the tumor cells had adhered
completely, CIK cells were added at diﬀerent ratios of
eﬀector:target (1:1, 1:5, 1:10, 1:20, and 1:50), in 200μl
of medium without serum. After incubation for 24 hours,
the supernatant in each well was removed and the cells
washed three times. Aliquots of 100μl of medium without
serum and 10μl of MTT were mixed and added to each
well. After incubation at 37◦C for 4h, the supernatant
was removed carefully, and 150μlo fD M S Ow e r ea d d e d
to each well. The cells were then shocked for 10min in
the dark. The OD was assessed by spectrophotometry at a
wavelength of 492nm. As a control, PBMCs were subjected
to the same procedure. The amount of cell death was
calculated according to the following equation: death rate =
(ODcontrol −ODsample)/ODcontrol ×100%.
2.5. Pathological Observation. SW1116 cells were placed on
a slide putted in the culture capsule. When the cells reached
80% conﬂuence, CIK cells were added at an eﬀector: target
ratio of 1:20. After incubation for 24h, the slides were
washed twice, stained with hematoxylin and eosin (HE),
and sealed with neutral gum. We observed the shapes and
aggregation of the cells by light microscopy. Tumor speci-
mens were ﬁxed with 10% neutral formaldehyde solution for
24h, dehydrated in an ethanol gradient, made transparent
with dimethylbenzene, embedded in paraﬃn, sectioned at a
thickness of 3-4μm, and stained with HE.
2.6. Nude Mouse Xenograft Assay. Nude mice were obtained
from the Chinese People’s Liberation Army Academy of
Military Medical Science. The biologic license number was
SCXK-(Jun)2007-004. Nude mice were bred in an animal
institute that complied with good laboratory practice (Chi-
nese PLA General Hospital Animal Experiment Centre). On
day 0, 5 × 106 SW1116 cells were injected subcutaneously
into the nude mice. The nude mice were found to have
developed 0.2cm3 t u m o rn o d u l e sa f t e r5d a y s .T h e yw e r e
then randomly divided into four groups: the untreated
group, 5-ﬂuorouracil-(FU-)treated group, CIK-consecutive
treated group, and CIK-interval-treated group. In the 5-FU-
treated group, 5-FU was injected intravenously at 50mg/kg
every day for 5 days in total. In the CIK-consecutive treated
group, the mice were injected abdominally with CIK cells (5
× 107 cell/day) for 5 days. In the CIK-interval-treated group,
5×107 ofCIKcellswereinjectedabdominallyintomiceonce
every 5 days, that is, 5 times in 3 weeks. Tumor volumes and
body weights were measured every 2 days. Tumor volumes
were calculated by using the formula: length (mm) × width
(mm) × height (mm). On day 30, the mice were sacriﬁced,
and the tumors were weighed. To detect toxicity to the
animals, the body weights of the animals were measured.
After ﬁxing in formalin, the tumor tissues were stained with
HE. Pictures were taken randomly in 10 ﬁelds of vision,
and image processing software (Image-Pro Plus Version 4.5,
USA) was used to calculate the necrotic area.
2.7. Statistical Analysis. The results are shown as the mean ±
standard error of the mean (SEM) of triplicate determinants
(wells). Data were plotted using GraphPad Prism version
5.00. Two-way analysis of variance (ANOVA) was used toClinical and Developmental Immunology 3
determine the signiﬁcance of the diﬀerence between the
means of all experiments. A P value of less than.05 was
considered to be statistically signiﬁcant.
3. Results
3.1. Phenotype of the CIK Cells. Firstly, we established a
stable system for the expansion of CIK cells in vitro. PBMCs
from 15 individuals were cultured to generate CIK cells. The
phenotypes of the PBMC and CIK cells were examined by
FACS.ThePBMCpopulation contained50%CD3+ cells,4%
CD3+CD56+ cells, 27% CD3+CD8+ cells, 22% CD3+CD4+
cells, and 3% CD8+CD56+ cells (Figure 1(a)). After culture
for 14 days, the CIK cell population contained 98% CD3+
cells, 41% CD3+CD56+ cells, 77% CD3+CD8+ cells, and
20%CD3+CD4+ cells(Figure 1(b)).After14days,thecounts
of the total number of cells was increased by 130-fold.
The number of CD3+CD56+ cells was increased by 1300-
fold, whereas the number of killer T cells (CD3+CD8+)w a s
increased by 390-fold. The counts of the two types of cells
were evidently diﬀerent between the PMBC and CIK cells
(Figure 1(c)). The proportion of CD3+CD56+cells was <5%
before culture, but 35% after culture. CD3+CD56+ cells are
the main eﬀector cells; therefore the harvested suspension
cells were mature CIK cells. The phenotypes of the CIK cells
from the 15 individuals were not evidently diﬀerent, which
demonstrates that the method tested for the culture of CIK
cells is reproducible.
3.2. Cytotoxicity of CIK Cells In Vitro. Next, we examined
the antitumor eﬀect of CIK cells in vitro.C I Kc e l l sh a v e
been shown to demonstrate cytotoxicity in a non-MHC-
restricted manner. CIK cells show strong anti-tumor activity
against lung cancer, ovarian cancer, cervical cancer, and
other types of tumor cells in vitro [11–14]. In this study,
at an eﬀector:target ratio of 100:1, the mean percentage
lysis of SW1116 cells was 9% after the addition of fresh
PBMCs (Figure 2(a)). At eﬀector:target ratios of 1:1, 5:1,
10:1, 20:1, and 50:1, the mean percentage lysis after the
addition of CIK cells was 3%, 23%, 42%, 62%, and 68%,
respectively, for SW1116 cells and 2%, 13%, 32%, 48%, and
54%, respectively, for U251 cells (Figures 2(b) and 2(c)).
The CIK cells were suspension cells and therefore could not
adsorb to the slide on their own. The cells were observed
by HE staining after coculture of the CIK and SW1116
cells for 24h. The CIK cells were round and had a high
proportion of nucleoplasm, whereas the SW1116 cells were
irregular and had a low proportion of karyoplasm. The
CIK cells adsorbed and aggregated around SW1116 cells
(Figure 2(d)). Cytotoxicity tests showed that the CIK cells
had a strong ability to kill SW1116 cells as compared with
normal lymphocytes. HE staining showed that when CIK
cells and tumor cells were cultured together, the CIK cells
gathered around the tumor cells without MHC restriction or
speciﬁcity.
3.3. Antitumor Eﬀects of CIK Cells In Vivo. Finally, we
evaluated the inhibition of growth of colorectal cancer
xenografts by CIK cells. The two groups of mice treated with
CIK cells showed no signs of panic, irritability, weakness, or
other symptoms after CIK cells were injected abdominally.
Throughout the treatment period, there was no signiﬁcant
decline in the weight of the mice in these groups, whereas 5-
FU showed evident toxicity. After being treated with 5-FU,
the some symptoms, for example, moving slowly, urinary
and fecal incontinence, were observed in the nude mice. On
day 3, the weight of the mice decreased signiﬁcantly, and two
mice died within the treatment period (Figure 3(a)). Pre-
liminary experiments showed that nude mice had signiﬁcant
side eﬀects, in the abdominal cavity after injection of 5-FU,
whereas injection of 5 × 107 CIK cells did not result in any
toxicity.
Through the measurement of tumor volume and tumor
weight, we demonstrated a powerful antitumor activity
of CIK cells. The consecutive-treated and interval-treated
groups showed a reduction in tumor volume of 41% and
52%,respectively,whereasthe5-FUgroupshowedadecrease
in tumor volume of 43% (Figure 3(b)). On day 30, the
mice were sacriﬁced and the tumors isolated. In the control
group, the mean value of tumor weight increased to 1.448g
at 30 days after injection. In the consecutive-treated and
interval-treated groups, tumor growth was inhibited by 53%
and 62%, respectively, whereas in the 5-FU-treated group
tumor growth was inhibited by 54% (Figures 3(c) and 3(d)).
In this experiment, we found that there was a tendency
towards better eﬃcacy in the CIK-consecutive-treated group
as compared with the CIK-interval-treated group, but there
was no signiﬁcant diﬀerence between the two groups. HE
staining demonstrated that the necrotic area of the tumor
tissues was greater in the groups that had been injected
with CIK cells than in the other groups; the necrotic area
in the former measured up to 60%, as compared with 24%
for the control group (Figures 4(a) and 4(b)). Interestingly,
although the CIK cells and 5-FU both signiﬁcantly inhibited
tumor growth, the area of tumor necrosis after treatment
with CIK cells was signiﬁcantly higher than that observed
after treatment with 5-FU. Therefore, in the future it will be
of interest to investigate the mechanisms by which CIK cells
inhibit tumor growth.
4. Discussion
Adoptive immunotherapy has now been available for nearly
30 years. One of the ﬁrst prototypes was the lymphokine-
activated killer (LAK) cells. In clinical studies, LAK cells
demonstrated modest eﬃcacy against metastatic cancers
such as renal cell carcinoma and melanoma [15]. Subse-
quently, studies conﬁrmed that standard IL-2, stimulated
LAK cells had low antitumor activity, and it was diﬃcult to
g e n e r a t el a r g en u m b e r so fc e l l s[ 16–18]. The emergence of
LAK cells that accelerated the ﬁeld of cellular immunother-
apy with CIK cells was performed in Stanford [19]. CIK
cells possess a higher level of cytotoxic activity and a higher
rate of proliferation than LAK cells [20]. Over the past
20 years, the development of CIK cell immunotherapy for
the treatment of cancer has received considerable attention.
CIK cells exhibit a high rate of proliferation [21]; during
the culture period, CD3+CD56+ cells can expand by up to4 Clinical and Developmental Immunology
CD3 PerCP CD3 PerCP CD3 PerCP
C
D
4
F
I
T
C
23%
48%
C
D
8
P
E
27%
C
D
5
6
A
P
C
5%
CD8 PE
C
D
5
6
A
P
C
3%
100 101 102 103 104
100
101
102
103
104
100 101 102 103 104
100
101
102
103
104
100 101 102 103 104
100
101
102
103
104
100 101 102 103 104
100
101
102
103
104
PBMCs
(a)
18%
80%
79% 41% 38%
CD3 PerCP CD3 PerCP CD3 PerCP
C
D
4
F
I
T
C
C
D
8
P
E
C
D
5
6
A
P
C
CD8 PE
C
D
5
6
A
P
C
CIK
100 101 102 103 104
100
101
102
103
104
100 101 102 103 104
100
101
102
103
104
100 101 102 103 104
100
101
102
103
104
100 101 102 103 104
100
101
102
103
104
(b)
0
20
40
60
80
100
120
CD+
3 CD+
3 CD+
4 CD+
3 CD+
8 CD+
3 CD+
56 CD+
8 CD+
56
(
%
)
CIK
∗
∗
∗
∗
PBMCs
(c)
Figure 1: Phenotypic analysis of CIK cells. All cell samples were stained with PerCP-conjugated antibodies against CD3, FITC-conjugated
antibodies against CD4, PE-conjugated antibodies against CD8, and APC-conjugated antibodies against CD56. (a) Typical phenotypic
analysis of PBMCs. (b) Typical phenotypic analysis of CIK cells. (c) Comparison of the phenotypic analyses of PBMCs and CIK cells.
The PBMCs population was composed of 50% CD3+ cells, 4% CD3+CD56+ cells, 27% CD3+CD8+ cells, 22% CD3+CD4+ cells, and
3% CD8+CD56+ cells. After culture for 14 days, the CIK cells comprised 98% CD3+ cells, 77% CD3+CD8+ cells, 20% CD3+CD4+ cells,
38% CD8+CD56+ cells, and 41% CD3+CD56+ cells. Phenotypic comparison analysis was performed from 15 samples, and the results are
expressed as means ± SD. (∗P<. 05)Clinical and Developmental Immunology 5
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Figure 2: Cytotoxicity of CIK cells in vitro. (a) Cytotoxicity of PBMCs against SW1116 cells. (b) Cytotoxicity of CIK cells against SW1116
cells. (c) Cytotoxicity of CIK cells against U251 cells. At an eﬀector:target ratio of 100:1, the percentage lysis of SW1116 cells after the
addition of PBMCs was 9%. At eﬀector:target ratios of 1:1, 5:1, 10:1, 20:1, and 50:1, the percentage lysis after the addition of CIK
cells was 3%, 23%, 42%, 62%, and 68%, respectively, for SW1116 cells and 2%, 13%, 32%, 48%, and 54%, respectively, for U251 cells. (d)
Observation of the distribution of CIK cells by HE staining, ×100 and ×200. CIK cells adsorbed to and aggregated around the SW1116 cells.
For cytotoxic assay, each experiment was performed in triplicate and was repeated at least three times, and the results are expressed as mean
± SD. (∗P<. 05)
1000-fold [3]. In this study, we used culture dishes that had
been coated with a monoclonal antibody against CD3. The
isolated PBMCs were plated onto the coated dishes, and
IFN-γ and IL-2 were added to the medium. After four days,
the cells were removed from the coated dishes and cultured
further in the presence of IL-2. The cells were harvested
after 14 days. The total cells expanded by up to 130-fold,
and the CD3+CD56+ cells expanded by up to 1300-fold. The
phenotype, composition, and quantity of the cells were as
described in other reports [11, 14, 22].
Currently, the mechanisms of the genesis and develop-
ment of colorectal cancer remain unclear, but it is generally
agreed that the action of various factors in the tumor
enables the immune system to be evaded and results in
unlimited proliferation of tumor cells. Research has shown
that in the animal model of colorectal cancer and in
patients with colorectal cancer patients, antigen-speciﬁc
cytotoxic T lymphocytes (CTL) are induced [23]. Therefore,
colorectal cancer is immunogenic, but it is possible that
colorectal cancer still develops for the following reasons: (1)
in patients with colorectal cancer where expression of the
histocompatibility leukocyte antigen (HLA)-I was decreased
or absent [24], the lack of antigen presentation by the tumor
cells led to the induction of CTL responses. (2) Mutations
in peptide transporting molecules (TAP) may also aﬀect the
presentation of T cell epitopes [25]. (3) Colorectal tumors
express not only functional Fas ligand (FasL), which can
induce apoptosis in tumor inﬁltrating T cells that bear Fas,
but also Fas itself, which although expressed at lower levels
than in normal colon epithelium may make the tumor cells
susceptible to apoptosis [26–29]. (4) Surface expression of
the CD3 ζ (zeta) chain of the T cell receptor (TCR) is
decreased in tumor-inﬁltrating T lymphocytes (TIL) from
patients with colorectal cancer. (5) Colorectal cancer cells
secrete factors such as transforming growth factor beta
(TGF-β), which promotes tumor growth, and IL-10, which
inhibits the cell immune response. Given that colorectal
cancer is caused by the loss of immune function, only a few6 Clinical and Developmental Immunology
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Figure 3: Antitumor eﬀects of CIK cells in vivo. Nude mice (n = 30) were injected subcutaneously with 5 × 106SW1116 colorectal cancer
cells. In the CIK-consecutive-treated group, 5 × 108 CIK cells were injected abdominally into the mice once every day for 5 days. In the
CIK-interval-treated group, 5 × 108 CIK cells were injected abdominally into the mice once every 5 days on 5 occasions, namely 5 times
in 3 weeks. In the 5-FU-treated group, 5-FU was injected intravenously at 50mg/kg. Body weights were measured every 2 days (a). Tumor
volumes were calculated by using the formula: length (mm) × width (mm) × height (mm) (b). Representative photographs are shown (c).
On day 30, the mice were sacriﬁced, and the tumor weights were determined (d). Standard deviations and P-values were calculated with
Student’s t-test (P<. 05).
studies of the treatment of colorectal cancer by immunother-
apy have been undertaken. For example, among 30 patients
with colorectal cancer treated with LAK cells and IL-2, one
completeanti-tumorimmuneresponseandfourpartialanti-
tumor immune responses were seen [30]. In addition, 7
patients with metastatic colorectal carcinoma resistant to
chemotherapy were treated by transfusing autologous IL-2
modiﬁed CIK cells [31]. This pilot study demonstrated an
anti-tumor immune response of this approach in at least
partial patients.
Here, we provide evidence that CIK cells might be a
good candidate for colorectal cancer therapy. The major
eﬀector cells of CIK cells, namely those that show the
greatest cytotoxicity, are the subset of CD3+CD56+ cells
[6], which express both the T-cell marker CD3 and natural
killer cell marker CD56 and are termed non-MHC-restricted
T cells. These cells are capable of killing both autologous
and allogeneic tumor targets. The cytotoxicity of CIK cells
mightbemediatedviacontactbetweentheadhesionreceptor
lymphocyte function-associated antigen-l (LFA-l), which is
f o u n do na l lTc e l l s ,a n di t sc o u n t e rr e c e p t o r ,i n t e r c e l l u l a r
adhesion molecule-l (ICAM-l), which is located on the
surface of the target cells [7]. CIK cells possess cytoplasmic
granules which contain the protein perforin (cytolysin).
The mechanism of destruction of target cells includes the
vectorial exocytosis of the contents of the cytoplasmic
granules into the intercellular space by the eﬀector cell at
the site of target-cell contact [32, 33]. In the vitro studyClinical and Developmental Immunology 7
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Figure 4: Pathological observation of the necrotic area of the xenografts. HE staining ×200. Representative examples of the necrotic area in
the four diﬀerent groups are shown (a). Necrotic area was calculated with Image-Pro Plus Version 4.5 (b). Standard deviations and P values
were calculated with Student’s t-test (P<. 05).
by HE staining, the result showed CIK cells adhered to
the surface of SW1116 cells, and they possessed powerful
killing capacity for SW1116 cells. This result was consistent
with the killing of tumor cells by CIK cells. CIK cells are
eﬀective against FasL-positive malignant cells and cells with
multidrug resistance (MDR), and it has been observed that
a population of CIK cells migrated to tumor sites by the
7th hour after injection and remained detectable at these
sites for an additional 9 days [8, 34]. In agreement with
this, we observed in vivo that abdominal injection of only
5 × 107 CIK cells resulted in strong inhibition of colorectal
tumor growth. Although a similar eﬀect was observed with
5-FU, the CIK cells had low toxicity and few side eﬀects
as compared with the chemotherapy drug. In contrast to
chemotherapy drugs, which have a suppressive eﬀect on
immune cells, CIK cells not only kill tumor cells directly,
but also can themselves secrete many cytokines, such as IL-
2, TNF-α, and granulocyte macrophage colony-stimulating
factor (GM-CSF), which enhances the systemic anti-tumor
activity of the body. HE staining of tissue biopsies after
treatment with CIK cells revealed the presence of a large
area of necrosis around the tumor. We speculate that after
CIK cells have been injected into the body, they gather ﬁrst
around the tumor, and then a large number of CIK cells
inﬁltrate the tumor and cause necrosis. Further experiments
are required to conﬁrm this hypothesis.
5. Conclusions
There are several studies concerning adoptive cellular
immunotherapy with many solid tumors, but this is the
ﬁrst study to address colorectal cancer SW1116 cell lines.
In this paper, we observed the antitumor activity of CIK
cells against human colorectal cancer in vitro and in vivo.
Cells with the phenotype CD3+CD56+ are rare (1%–5%)
in uncultured peripheral blood lymphocytes [6, 19]. The
CIK cellspossessed the strong proliferation capacity; the CIK
cells derived from 50ml peripheral blood can be ampliﬁed
three folds as much as the quantity of normal human
lymphocytes. The results of the nude mouse xenograft
assay showed that the CIK-consecutive-treated and CIK-
interval-treated groups experienced a similar inhibitory
eﬀect to that observed with 5-FU. These results show that
immunotherapy with CIK cells is a suitable adjuvant therapy
for colorectal cancer. We propose that diﬀerent CIK cells
treatment programs will be used for diﬀerent patients in
clinical practice.
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